|
|
 |
|
Viewing report
|
|
|
|
Poland Pharmaceuticals and Healthcare Report Q1 2011
Business Monitor International, Nov 2010, Pages: 91
Poland Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Poland's pharmaceuticals and healthcare industry.
Poland is an important pharmaceutical market in Central and Eastern Europe (CEE), and is a relatively well-developed market compared with those to the east. Poland’s total drug expenditure and projected growth rates are below Russia and Turkey’s respective figures. However, Poland’s considerably more favourable business environment makes it a more attractive investment opportunity, which is illustrated in BMI’s latest Pharmaceuticals and Healthcare Business Environment Ratings (BERs) index. Poland remains in second place in CEE for Q111, with an overall score of 62.5. A strong performance in 2009 and significant growth projected for 2010 & 2011 benefit the high Industry Rewards score. The BER score has edged above the Q410 figure as a result of an improved Country Risk outlook. BMI forecasts that Poland’s pharmaceutical market will increase from PLN30.25bn (US$10.56bn) in 2009 to PLN32.23bn (US$11.13bn) in 2010. Between 2009 and 2014, BMI projects a compound annual growth rate (CAGR) of 7.04% in local currency terms and 8.80% in US dollar terms.
A multinational survey in 2010 has revealed that Poland is considered to have one of the worst healthcare systems in Europe and that public opinion is split on how to resolve the issue. The Polish respondents identified a lack of public funding as the most significant upcoming threat to their healthcare system. A total of 30% of respondents favoured increasing private insurance, optional supplemental insurance or supplemental policies from mutual insurance companies, while 28% preferred increased taxes or compulsory contributions.
On October 10 2010, the Ministry of Health submitted the latest draft act on the reimbursement of medicines, which is one of the most significant components of the healthcare reform. The draft legislation includes a fixed wholesale mark-up of 5% on reimbursed prescription drugs. The method for establishing reference drugs for reimbursement calculations is also to be changed. The existing reimbursement categories are to be maintained but with more precise criteria. The draft bill states that 17% of the total annual budget of the Polish National Health Fund (NFZ) is to be spent on the reimbursement of medicines. In addition, the legislation includes regulation for the establishment of formal risk-sharing agreements, associated with the proposed increase in NFZ spending.
Poland’s macroeconomic economic outlook is encouraging. BMI reiterates their long-held view that Poland will prove a growth outperformer over the short and long term, as the nation's domestic demand base shields the economy from the worst of the global headwinds, while economic convergence with Western Europe propels higher living standards.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Poland Pharmaceuticals and Healthcare Report Q2 2012
Poland Pharmaceuticals and Healthcare Report Q4 2010
Serbia Pharmaceuticals and Healthcare Report Q1 2011
Poland Pharmaceuticals and Healthcare Report Q3 2011
Kazakhstan Pharmaceuticals and Healthcare Report Q1 2011
Bulgaria Pharmaceuticals and Healthcare Report Q1 2011
Poland Pharmaceuticals and Healthcare Report Q3 2010
Ukraine Pharmaceuticals and Healthcare Report Q1 2011
Italy Pharmaceuticals and Healthcare Report Q1 2011
Sweden Pharmaceuticals and Healthcare Report Q1 2011
|
|
|
|
